European Annals of Allergy and Clinical Immunology THE OFFICIAL JOURNAL OF AAITO THE OFFICIAL JOURNAL OF SPAIC HOME PAGE

EDITORS IN CHIEF
L. Cecchi (Firenze - Italy)

P. Carreiro-Martins (Lisbon - Portugal)

 

HONORARY EDITOR
A. Sabbah (Angers - France)

 

ASSOCIATE EDITORS
R. Rodrigues Alves (Lisbon - Portugal)
A. Tedeschi (Milano - Italy)

 

EDITORIAL BOARD
M. Morais-Almeida (Lisbon - Portugal)
R. Asero (Milan - Italy)
M.B. Bilò (Ancona - Italy)
F. Bonifazi (Ancona - Italy)
L.M. Borrego (Lisbon - Portugal)

K. Brockow (München - Germany)
A.À. Cruz (Salvador - Brasil)
L. Delgado (Oporto - Portugal)
P. Demoly (Montpellier - France)
G. D'Amato (Napoli - Italy)
M. Drouet (Angers - France)
M. Fernandez-Rivas (Madrid - Spain)
A. Fiocchi (Milano - Italy)

J. Fonseca (Oporto - Portugal)
D. Macchia (Firenze - Italy)
F. Mastrandrea (Taranto - Italy)
M. Maurer (Berlin - Germany)
G. Moscato (Pavia - Italy)
A. Musarra (Reggio Calabria - Italy)
C. Nunes (Portimao - Portugal)
M. Olivieri (Verona - Italy)
P. Parronchi (Firenze - Italy)
G. Passalacqua (Genova - Italy)
G. Pauli (Strasbourg - France)
E. Pedro (Lisbon - Portugal)
A. Perino (Torino - Italy)
L.K. Poulsen (Copenaghen - Denmark)
O. Quercia (Faenza - Italy)
A. Romano (Roma - Italy)
E. Scala (Roma - Italy)
D. Solé (Sao Paulo - Brasil)
A. Todo Bom (Coimbra - Portugal)
S. Voltolini (Genova - Italy)

 

SCIENTIFIC COMMITTEE
L. Antonicelli (Italy)
A. Bener (Turkey)
H. Bazin (Belgium)
J. Bellanti (USA)
C. Geller-Bernstein (Israel)
M. Cugno (Italy)
B. David (France)
S. Durham (UK)
G.P. Girolomoni (Italy)
R. Jarish (Austria)
S.G.O. Johansson (Sweden)
F. Levi-Shaffer (Israel)
H. Lowenstein (Denmark)
J.L. Malo (Canada)
A.G. Palma-Carlos (Portugal)
G. Scadding (UK)
G. Scadding (UK)
E. Stevens (Belgium)
R. van Ree (Netherlands)

 

FOUNDER AND CORRESPONDING MEMBER
G.M. Halpern (USA)


*************************

Editors in Chief
Lorenzo Cecchi
Pedro Carreiro-Martins

Chief Business & Content Officer
Ludovico Baldessin

Publishing Editor

Chiara Scelsi

c.scelsi@lswr.it
Ph. 0039 (0)2-88184.257


Production Manager

Walter Castiglione
w.castiglione@lswr.it
Ph. 0039 (0)2-88184.222

Sales
Stefano Busconi
dircom@lswr.it
Ph. 0039 (0)2-88184.404

Printing
Mccgraphics
Pol. Ind. Txirrita Maleo Pab 11
20100 Errenteria (Gipuzkoa), Spain

EDRA SpA
Via G. Spadolini, 7
20141 Milano - Italy
Ph. 0039 (0)2-88184.1
Fax 0039 (0)2-88184.301 
www.edizioniedra.it

Contents »

Cost-effectiveness of the SQ HDM SLIT-tablet for the treatment of allergic asthma in three Eastern European Countries


W. Green1william.green@york.ac.uK, J. McMaster1, R. Babela*2,3, S. Buchs3

Show more: Authors information and Publication history

Doi
https://doi.org/10.23822/EurAnnACI.1764-1489.78

Summary
Background. The standardized quality (SQ®) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet (acarizax®, ALK-Abelló A/S, Hørsholm, Denmark) is an allergy immunotherapy tablet for people with allergic respiratory disease. This analysis aims to assess the cost-effectiveness of the SQ HDM SLIT-tablet from the perspective of three Eastern European countries: Czech Republic, Poland and Slovakia. Methods. A cost-utility model per country was developed, which compared the SQ HDM SLIT-tablet as add-on to pharmacotherapy with pharmacotherapy alone in patients with HDM allergic asthma (AA) over a five year time horizon. The effectiveness of the two interventions was based on the results from a large-scale randomised controlled trial. In the models, annual costs and quality-adjusted life year (QALY) scores from the trial were extrapolated over a five year period, and the incremental cost-effectiveness ratios (ICERs) were estimated. One-way deterministic sensitivity and scenario analyses were undertaken. Results. The SQ HDM SLIT-tablet is cost-effective in all three markets over the five year time horizon (ICERs of less than € 10,000 per additional QALY). Treatment with the SQ HDM SLIT-tablet improves patient outcomes, with QALY gains of 0.35, versus pharmacotherapy only. In all three countries, the SQ HDM SLIT-tablet also incurs increased costs compared to pharmacotherapy treatment only. The sensitivity analysis identified utility values from the clinical trial as the main driver of the model results. Conclusion. The SQ HDM SLIT-tablet is a cost-effective treatment option for people with HDM AA in three different health care settings in Eastern Europe.

Key words
cost-effectiveness; allergic asthma; allergy immunotherapy; sublingual immunotherapy; SQ HDM SLIT-tablet